Devinder Bhrany
Flint, MINPI 1144225137
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 504 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.
Across 504 payments — averaging $13.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$802
- Novartis$661
- Teva Pharmaceuticals USA, Inc.$614
- AbbVie$603
- Amgen$544
- Supernus Pharmaceuticals, Inc.$404
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$1112%
- Food & beverage$6,61798%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 81 | $802 |
| Novartis | 56 | $661 |
| Teva Pharmaceuticals USA, Inc. | 55 | $614 |
| AbbVie(2 entities) | 51 | $603 |
| Amgen(2 entities) | 40 | $544 |
| Supernus Pharmaceuticals, Inc. | 29 | $404 |
| Eisai Inc. | 21 | $323 |
| MDD US Operations, LLC | 35 | $305 |
| Sanofi | 13 | $231 |
| Upsher-smith Laboratories LLC | 10 | $188 |
| Bristol Myers Squibb | 7 | $183 |
| Neurocrine Biosciences, Inc. | 9 | $174 |
| Neurelis, Inc. | 8 | $155 |
| Acorda Therapeutics, Inc | 9 | $141 |
| Lilly USA, LLC | 8 | $141 |
| UCB, Inc. | 6 | $128 |
| Kyowa Kirin, Inc. | 8 | $126 |
| Avanir Pharmaceuticals, Inc. | 6 | $113 |
| EMD Serono, Inc. | 7 | $112 |
| E.r. Squibb & Sons, L.L.C. | 4 | $96 |
| Lundbeck LLC | 6 | $89 |
| Acadia Pharmaceuticals Inc | 5 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $71 |
| Alnylam Pharmaceuticals Inc. | 3 | $61 |
| AstraZeneca | 2 | $47 |
| Tanabe Pharma America, Inc. | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| SK Life Science, Inc. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| Zyla Life Sciences, Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Adamas Pharmaceuticals, Inc. | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.